T. Rowe Price Associates’s Ascendis Pharma ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $343M | Sell |
|
|||||
|
2025
Q2 | $324M | Sell |
|
|||||
|
2025
Q1 | $352M | Sell |
|
|||||
|
2024
Q4 | $314M | Buy |
|
|||||
|
2024
Q3 | $317M | Buy |
|
|||||
|
2024
Q2 | $243M | Buy |
|
|||||
|
2024
Q1 | $269M | Buy |
|
|||||
|
2023
Q4 | $182M | Sell |
|
|||||
|
2023
Q3 | $153M | Sell |
|
|||||
|
2023
Q2 | $184M | Sell |
|
|||||
|
2023
Q1 | $361M | Sell |
|
|||||
|
2022
Q4 | $453M | Sell |
|
|||||
|
2022
Q3 | $400M | Sell |
|
|||||
|
2022
Q2 | $480M | Buy |
|
|||||
|
2022
Q1 | $572M | Buy |
|
|||||
|
2021
Q4 | $641M | Sell |
|
|||||
|
2021
Q3 | $771M | Sell |
|
|||||
|
2021
Q2 | $666M | Sell |
|
|||||
|
2021
Q1 | $654M | Sell |
|
|||||
|
2020
Q4 | $1.1B | Sell |
|
|||||
|
2020
Q3 | $1.05B | Sell |
|
|||||
|
2020
Q2 | $1.04B | Sell |
|
|||||
|
2020
Q1 | $810M | Sell |
|
|||||
|
2019
Q4 | $1.08B | Sell |
|
|||||
|
2019
Q3 | $749M | Buy |
|
|||||
|
2019
Q2 | $827M | Buy |
|
|||||
|
2019
Q1 | $550M | Buy |
|
|||||
|
2018
Q4 | $258M | Buy |
|
|||||
|
2018
Q3 | $240M | Buy |
|
|||||
|
2018
Q2 | $206M | Buy |
|
|||||
|
2018
Q1 | $184M | Buy |
|
|||||
|
2017
Q4 | $18.2M | Buy |
|